Veeva Systems Inc Class A (VEEV)

Investment Committee Summary

Investment Thesis

At $248 on 25 August 2026, Veeva is capitalised at roughly 28x forward earnings on an operating margin of 50% — a rating that embeds durable subscription growth and margins persisting at that level through the cycle. Our work is more cautious on both. The shares are trading rich to the triangulated fair value of $162, a gap of -35%, with the probability-weighted expected value at $160 and the twelve-month target at $162. The scenario set carries a genuine funding-and-utilisation reset alongside a structural-impairment path whose target sits below the 52-week low, and the blend across those states is what pulls the number down. Among the cross-checks, the discounted cash-flow anchor and the peer read on enterprise value to revenue both land near the triangulated figure; the forward-earnings peer read is the outlier and rests on multiple rather than cash, so we do not lean on it. The Monte Carlo attributes the great majority of variance to the multiple, making this a de-rating question more than an operating one. The balance sheet (net cash of ~$1.8B) is a cushion, not a thesis. Hence SELL. The single most damaging risk is a sustained contraction in biopharma research funding that compresses growth and the multiple together.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($248) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear mechanism is a funding and utilisation reset, and it is concrete rather than a hedge. Biopharma sponsors and contract research organisations cut research and clinical budgets when funding tightens; seat- and module-based subscriptions then stall as customers defer expansion and trim usage rather than churn outright — slower to appear and therefore harder to price. Revenue growth fades toward flat, and against a cost base built for expansion, the operating margin compresses from 50% on negative leverage. A software franchise carried at 28x forward earnings does not keep that rating through a simultaneous growth and margin disappointment: the multiple compresses in the same move, which is why the modelled variance sits overwhelmingly in the multiple rather than in the operating line. If the reset proves structural rather than cyclical, the path targets a level below the 52-week low.

Key Debate

P/E Multiple explains 86% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 27.4× consensus forward EPS, vs the house DCF terminal 15.0×, and a peer median 26.5×. The house DCF sits 31% below spot, so the market is pricing in more than the house case — roughly 3.9pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($73.20) to a 'Bull — Re-Rate' bull case ($272); the probability-weighted blend (PWEV $160) is -35% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 14% of revenue; free cash flow net of SBC is $0.91B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $73.20). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $119). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $168). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $224). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $272). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $146 and 5% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (86% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 15.0x terminal FCF multiple → $171. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $131; the peer-median forward P/E is 26.5x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 25% of the median — moderate (healthy method disagreement — read the blend with care).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Life-Science Tools, Services & Software multiple (AI re-rating) (base 18.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 26.4× (simple median 26.5×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $148–$310, centre $214 (-14% vs spot); spot sits at the 62nd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $272.

Company Overview & Business Model

Veeva Systems Inc Class A — HEALTHCARE · HEALTH INFORMATION SERVICES. Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

How it makes money.

Edge. Wide moat — A wide moat rooted in regulated-workflow switching costs and de-facto industry-standard status justifies a terminal multiple above the market; if Vault/CRM churn proves it is only narrow (sponsors migrate off Veeva CRM to Salesforce Life Sciences without operational penalty), the terminal multiple should compress toward ~18-20x rather than the high-20s the base assumes.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2026-01-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 156% — cash-backed.

Competitive Moat

Moat sources:

• Validated-system switching costs: Vault deployments carry GxP/CSV validation that must be re-run on any migration
• Data-network standard: Veeva OpenData/Crossix reference data embedded in pharma commercial workflows
• Regulatory-workflow lock-in across QualityDocs, RIM and eTMF used for FDA/EMA submissions
• Absence of a like-for-like validated competitor at scale outside Salesforce's departing CRM partnership

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.48 vs analyst floor +0.01 → delta +0.47 (n=32 mgmt / 27 Q&A; 64th pctile across the S&P book, z +0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 155 articles): avg ticker sentiment +0.17 (bullish 27% / bearish 3%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-08-26 (~2d) — Quarterly earnings — est. EPS $1.62 (AV EARNINGS_CALENDAR)
• 2026-09-15 (~22d) — Vault CRM migration cutover milestone as legacy Veeva-on-Salesforce sunsets (multi-year migration) (authored)
• 2026-12-08 (~106d) — Veeva World customer summit product roadmap (AI Direct Data API + Vault agents) (authored)
• 2027-03-01 (~189d) — FY2027 guidance with full Vault CRM cohort transitioned (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +7.5%.
• Prior-forecast backtest (13 snapshots, 2026-06-27→2026-08-20): directional hit-rate 0%; mean predicted -18.4% vs realised +25.1%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 16 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Subscription revenue year-on-year growth < 0.025 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Non-GAAP operating margin < 0.47 (2 consecutive prints). Base operating margin is 0.504; the R&D-recession path assumes 0.44. A sustained print below 0.47 signals negative operating leverage consistent with the bear mechanism rather than one-off investment.
• Subscription net retention / calculated billings growth < 1.05 (2 consecutive prints). A net-retention or billings figure sliding toward 1.05 shows customers trimming seats and modules as biopharma budgets tighten — the leading edge of the funding-reset scenario before it reaches headline revenue.
• FY revenue guidance versus consensus < 3.4 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Free cash flow margin < 0.34 (2 consecutive prints). The DCF leans on high cash conversion off a capital-light base. A sustained free-cash-flow margin below 0.34 would undercut the terminal-value bridge and question the mid-cycle cash-generation assumption.

Fact / Inference / Speculation

• FACT: Spot $248; 52-week range $148–$310; engine rating SELL; house target $162 (-35%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $162 (-35% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

71.2/100 (confidence band 55.7–86.7), 94th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 71.7 → 71.7 → 72.0 → 71.4 → 71.4 → 71.3 → 71.3 → 71.3.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $160.45.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.30, vs QQQ +0.25 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Collar. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with rich premium — finance downside protection by selling an expensive call (collar)
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 88th percentile of the cross-section → high vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 92nd percentile of its own month-end history (decile 10).
• Earnings in ~1d (2026-08-26): expect an IV crush after the print — prefer defined-risk structures and avoid naked short premium into the event.
• IV term structure is in backwardation (near-dated richer, slope -8.8pp) — front-month premium is elevated; favour selling the near tenor / shorter-dated structures.

IV term structure (backwardation, slope -8.8pp): 25-DTE 57% · 116-DTE 49% · 389-DTE 48%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

⚠ Earnings in ~1d (2026-08-26): expect an IV crush after the print — prefer defined-risk structures and avoid naked short premium into the event.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 57.1% (elevated regime) · expected move ±11.7% (2026-09-18) · put/call OI 0.42 · ATM Δ 0.52 / Θ -0.30 / ν 0.26 · next earnings 2026-08-26. Direction: SHORT/HEDGE (implied return -34.7% to triangulated fair value $162.28).

Bear Put Spread (Bearish) — Long 250 P / Short 175 P · 2027-03-19 · net debit $26.5 · max profit $48.50 · breakeven $223.50 · RoR 183.0% · max loss $26.50 · priced from the listed chain (EOD marks)

Defined-risk downside expression: the debit caps the loss, with the position gaining as the stock falls toward the lower strike — a way to act on a bearish view without shorting stock. Illustrative — no outcome is implied or guaranteed.

Protective Put (if held) (Hedge) — Long 250 P · 2027-03-19 · premium $33.8 · floor 1.0% · max loss $33.80 · priced from the listed chain (EOD marks)

Insurance for an existing holding — a known premium buys a floor while leaving the upside intact. A way to hold through a binary event or volatility with defined downside.

Protective Collar (if held) (Hedge) — Long 220 P / Short 270 C · 2027-03-19 · net $9.5 · floor -11.0% · cap +9.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling. Elevated implied volatility currently enriches the premium collected.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -35% vs spot
• Monte Carlo median implies -41% vs spot
• DCF fair value implies -31% vs spot
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -71% vs spot
• Net: the valuation anchor itself sits 34.7% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $7B + PV(terminal) $19B = EV $26B; + net cash $1.8B → equity $28B ÷ diluted shares $0.16B = $171/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $187/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 227% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $131 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (41.0); Terminal × ±15% (35.0); Op margin ±3pp (18.0); WACC ±1pp (13.0); Capex intensity ±15% (1.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 15×, FY+5 revenue $4B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.